Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who ...

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

Romvimza is a medicine called a kinase inhibitor that is used to treat tenosynovial giant cell tumor (TGCT ... how much the ROM was improved after treatment, and change from baseline in the ...

A longitudinal assessment of patient-reported outcomes demonstrated that pexidartinib (Turalio) continues to offer clinically meaningful symptom relief with extended use in patients with tenosynovial ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

Merck KGaA, Darmstadt, Germany, a science and technology company, has entered into a definitive agreement to acquire ...

By modulating key signaling pathways and cellular interactions within the TME, lncRNAs are involved in processes critical to tumor progression, such as remodeling of the ECM, immune cell ...

Imagine a super-charged immune cell that can launch a ... can be remotely controlled to target tumors using focused ultrasound, potentially making treatments safer yet more effective.